GPX4 and cancer: (50) discovered that GPX4 is associated with chemoresistance in colorectal cancer, and that inhibiting the IF20A/NUAK1/Nrf2/GPX4 signaling pathway can increase cancer cell sensitivity to oxaliplatin.